SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Veradermics, Inc

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

922967104

(CUSIP Number)

Kelly Zelezen
Kleinberg, Kaplan, Wolff & Cohen, P.C., 500 Fifth Avenue
New York, NY, 10110
2129866000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/01/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

922967104

Name of reporting person

Seven Fleet Master Fund LP

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 80,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 80,000.00

Aggregate amount beneficially owned by each reporting person

80,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP Number(s):

922967104

Name of reporting person

Seven Fleet Capital Management LP

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 80,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 80,000.00

Aggregate amount beneficially owned by each reporting person

80,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP Number(s):

922967104

Name of reporting person

Seven Fleet Capital Management GP LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 80,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 80,000.00

Aggregate amount beneficially owned by each reporting person

80,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP Number(s):

922967104

Name of reporting person

Brian Liu

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 80,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 80,000.00

Aggregate amount beneficially owned by each reporting person

80,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, par value $0.00001 per share

(b)

Name of Issuer:

Veradermics, Inc

(c)

Address of Issuer's Principal Executive Offices:

470 JAMES STREET, NEW HAVEN, CONNECTICUT , 06513.

Item 1 Comment:

The following constitutes the Schedule 13D filed by the undersigned (the "Schedule 13D") relating to the Common Stock, $0.00001 par value per share (the "Shares") of Veradermics, Incorporated (the "Issuer").

Item 2.

Identity and Background

(a)

This joint statement on Schedule 13D is being filed by Seven Fleet Master Fund LP ("Seven Fleet Master Fund"), Seven Fleet Capital Management LP ("Seven Fleet Management"), Seven Fleet Capital Management GP LLC ("Seven Fleet Management GP" and together with Seven Fleet Master Fund and Seven Fleet Management, the "Reporting Entities") and Dr. Brian Liu (the "Reporting Individual"). The Reporting Entities and the Reporting Individual are collectively referred to as the "Reporting Persons."

(b)

The address of the principal business office of each Reporting Person is 960 San Clemente Way, Mountain View CA 94043.

(c)

The principal business of Seven Fleet Master Fund is acquiring, holding and disposing of investment securities. The principal business of Seven Fleet Management is serving as the investment manager of Seven Fleet Master Fund. The principal business of Seven Fleet Management GP is serving as the general partner of Seven Fleet Management. The principal business of Dr. Liu is serving as the managing member of Seven Fleet Management GP.

(d)

No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

Seven Fleet Master Fund is a limited partnership organized under the laws of the Cayman Islands. Seven Fleet Management is a limited partnership organized under the laws of the State of Delaware. Seven Fleet Management GP is a limited liability company organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

Item 3.

Source and Amount of Funds or Other Consideration

The Shares held by Seven Fleet Master Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 80,000 Shares beneficially owned by Seven Fleet Master Fund is approximately $8,000,000, excluding brokerage commissions.

Item 4.

Purpose of Transaction

The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in Item 4(a) through (j) of this Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board, engaging in discussions with stockholders of the Issuer or third parties, including potential acquirers and service providers, about the Issuer and the Reporting Persons' investment, making proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, including a sale of the Issuer as a whole or in parts, Board structure (including Board composition) or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4.

Item 5.

Interest in Securities of the Issuer

(a)

The percentages used in this Schedule 13D are based upon 41,184,080 Shares outstanding, which is the sum of (i) 37,340,290 Shares as of March 25, 2026, as reported in the Issuer's Annual Report on Form 10- K, filed with the Securities and Exchange Commission on March 30, 2026, and (ii) the 3,843,790 Shares sold by the Issuer pursuant to its Registration Statements on Form S-1 (File Nos. 333-295356 and 333-295420), as disclosed in the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 1, 2026. See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Shares and percentage of the Shares beneficially owned by each of the Reporting Persons. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own. Longitude Capital Management Co. LLC (together with its affiliates, "Longitude") and Seven Fleet Management have instituted policies and procedures that may affect the acquisition, holding and disposition of securities held by Seven Fleet. As a result of such policies and procedures, the Reporting Persons and Longitude may be deemed to be members of a group within the meaning of Section 13(d)(3) of the Exchange Act. As of the date hereof, based on information provided by or on behalf of Longitude, Longitude may be deemed to be the beneficial owner of 4,653,873 Shares, constituting 11.3% of the number of Shares outstanding (calculated based on the total Shares outstanding as set forth above in this Section 5(a)). Notwithstanding such policies and procedures, the Reporting Persons expressly disclaim such group membership and beneficial ownership over any Shares that they may be deemed to beneficially own by reason of such policies and procedures. This Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 of the Exchange Act or for any other purpose.

(b)

See rows (7) through (10) of the cover pages to this Schedule 13D, including the notes relating thereto, for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and the sole or shared power to dispose or to direct the disposition.

(c)

The Reporting Persons have not entered into any transactions in the Common Stock during the past sixty days, except as follows: (i) On May 1, 2026, Seven Fleet Master Fund purchased 80,000 Shares at a purchase price of $100.00 per Share, excluding commissions, pursuant to the Issuer's follow-on offering.

(d)

No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

On May 5, 2026, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7.

Material to be Filed as Exhibits.

Ex. 99.1 Joint Filing Agreement to Schedule 13D by and among Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC and Dr. Brian Liu.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Seven Fleet Master Fund LP

Signature:	/s/ Dr. Brian Liu
Name/Title:	Dr. Brian Liu, Managing Member of Seven Fleet Capital Management LP, its Investment Mgr and Seven Fleet Capital Management GP, LLC, its Gen'l Ptr
Date:	05/05/2026

Seven Fleet Capital Management LP

Signature:	/s/ Dr. Brian Liu
Name/Title:	Dr. Brian Liu, Managing Member of Seven Fleet Capital Management GP, LLC, its General Partner
Date:	05/05/2026

Seven Fleet Capital Management GP LLC

Signature:	/s/ Dr. Brian Liu
Name/Title:	Dr. Brian Liu, Managing Member
Date:	05/05/2026

Brian Liu

Signature:	/s/ Dr. Brian Liu
Name/Title:	Dr. Brian Liu
Date:	05/05/2026

SEC Form SCHEDULE 13D filed by Veradermics Incorporated